AprilBio Amends Rights Issue Disclosure – Changes Third-Party Allottee to SPC, Terms Unchanged


  • This amendment changes one of the third-party allottees from IMM Asset Management to the special purpose company IMM Healthcare No. 8, but all key terms of the rights issue remain unchanged.
  • With the payment of subscription on July 23, 2026, 4,095,456 new shares are issued, resulting in approximately 17.5% dilution relative to existing shares. The largest shareholder will change to IMM Healthcare No. 8.
  • The new shares are subject to a one-year lock-up, and the proceeds will be fully used for R&D. The funding structure involves credible institutional investors including IMM Asset Management, KDB Capital, and the National Pension Service.
  • [AI Summary]This amendment finalizes the structural details of the capital increase without altering the original terms, resulting in a neutral impact on shareholder value. However, the 17.5% dilution remains a tangible burden.

KOSDAQ Filing Information


  • [Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)
  • Company: AprilBio (397030)
  • Submission: AprilBio Co.,Ltd.

  • Shares: 23,413,826
  • Price: 24,500 KRW
  • Market Cap: 573.6 B KRW